Skip to content
EntityQ27076996· pop 7· linked from 489 articles

ripretinib

Sign in to save

Also known as Qinlock, DCC-2618

Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. It is taken by mouth. Ripretinib inhibits the activity of the kinases KIT and PDGFRA, which helps keep cancer cells from growing.

~7 min read

Encyclopedic overview

9 sections
Contents
  • Medical uses
  • Adverse effects
  • History
  • Society and culture
  • Legal status
  • Names
  • References
  • Further reading
  • External links

{{Infobox drug | image = Ripretinib skeletal.svg | image_class = skin-invert-image | width = | alt = | caption =

| pronounce = rip re' ti nib | tradename = Qinlock | Drugs.com = | MedlinePlus = a620035 | DailyMedID = Ripretinib | pregnancy_AU = D | pregnancy_AU_comment = | pregnancy_category= Use should be avoided | routes_of_administration = By mouth | class = | ATC_prefix = L01 | ATC_suffix = EX19 | ATC_supplemental =

Excerpted from Wikipedia’s “ripretinib” article, available under the CC BY-SA 4.0 licence.

Available in 7 languages

via Wikidata sitelinks · CC0